Yes. Humira (adalimumab) has several biosimilars. Biosimilars are highly similar to the original product and are approved to treat the same conditions (e.g., rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, ankylosing spondylitis, etc.). They’re not exact generics, but they have no clinically meaningful differences in safety or effectiveness.
A few key points:
- Interchangeability: In the U.S., a biosimilar can be substituted at the pharmacy level as an “interchangeable” product only if the FDA designates it as interchangeable and state laws allow it. As of now, no adalimumab biosimilar has been designated interchangeable by the FDA, so substitution rules depend on location and prescriber/payer policies.
- Availability: Several adalimumab biosimilars are approved and marketed in the U.S. and Europe, including well-known options like Amjevita (adalimumab-atto) and Cyltezo (adalimumab-adbm). Other biosimilars exist in the market or in development, with different brands in various countries (for example, Hyrimoz, Idacio, Abrilada, Imraldi in various markets). Availability varies by country and payer.
- Cost: Biosimilars typically offer lower prices than Humira, but exact costs depend on your country, insurer, and contract rebates.
If you’d like, tell me:
- Your country or region (US, EU country, etc.)
- Whether you want a quick list of currently available biosimilars in your area
- Whether you’re considering switching from Humira or starting a biosimilar
I can look up the up-to-date options and help compare them (brand names, manufacturer, indications, and basic considerations). And as always, discuss any switch with your rheumatologist or gastroenterologist, since they can tailor the choice to your medical history and insurance.